Moreover, the PF-04691502 inhibitor reduced AKT and S6RP phosphorylation leading to the inhibition of cell proliferation in cancer cells harboring PI3Kα mutations and PTEN deletions [136]. This evidence concerns the gene AKT1 and cancer.